Pharmaceutical company Bioglan Pharma has expanded its links with Novartis, having already acquired a number of steroid products for the German market from Novartis.
Bioglan has licensed and has the option to acquire rights to Locacorten, Locasalen and Sicorten for a further 35 countries. These products are used to treat inflammatory skin conditions.
CEO Terry Sadler said the deal would particularly help Bioglan's plans for expansion into Italy and Spain. The agreement also covers countries in the Middle East, Africa, Asia and Australasia.
Dermatology is one of Bioglan's main specialist areas, accounting for 62% of product sales for its financial year to the end of January 2000.
